The Board

Johan Bygge

Chairman of the board

Chairman of the board since May 2021. Johan Bygge holds a Master of Science from Stockholm School of Economics.

Previous experience: Chairman of EQT Asia Pacific, COO EQT, CFO Investor AB, Deputy CEO Electrolux, CFO Electrolux. Board member of Anticimex, PSM Ltd, I-Med, ILA Vietnam, Sanitec Oy, Hi3G Scandinavia, Rådet för god sed på Aktiemarknaden, etc.

Other assignments: Chairman of the board of Scandi Standard AB (publ) and Yangi AB. Deputy chairman of the board of Tredje AP-fonden (AP3). Board member of Getinge AB, Capman Plc, Lantmännen ek för. SNS Förtroenderåd etc.

Shareholding: 6,286 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Khatereh Ahmadi

Non-Executive Member of the board

Board member since May 2024. Dr. Khatereh Ahmadi has a PhD in biochemistry from King's College London and held a post-doctoral position at the Ludwig Institute for Cancer Research in London. She also holds an MBA from Henley Management College.

Previous experience: With over 20 years of experience in the pharmaceutical industry, Dr Khatereh Ahmadi currently holds the role of Head of Search and Evaluation Business Development Europe & Middle East at MSD, where she has also been actively involved in business development and licensing in the oncology space in Europe. Prior to joining MSD, she was co-founder and CEO of reViral Ltd, a biotechnology company focused on antiviral therapies. Under her leadership, the company secured a $21 million Series A funding round with investors such as Andera Partners and Orbimed. Dr. Ahmadi also played a critical role in founding the oncology company Piramed Ltd where she became head of business development and negotiated a comprehensive license agreement with Genentech and later acquisition by Roche. Dr. Ahmadi has also been a consultant to a number of companies in the EU and the US in the field of oncology..

Other assignments: Head of Search and Evaluation Business Development Europe & Middle East at MSD

Shareholding: 0 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Göran Forsberg

Non-Executive Member of the board

Board member since May 2019. Born 1963. Göran Forsberg is a PhD in Biochemistry and Associate Professor.

Previous experience: Göran Forsberg has more than 30 years of experience from pharmaceutical development in both the Biotech industry and in large pharmaceutical companies. He has extensive experience of many different parts of drug development, as well as business development and investor relations. Göran Forsberg is the CEO of Cantargia AB since 2014. Prior to that, he worked as a business development manager at Active Biotech. Previous experience comes from positions at Pharmacia, KabiGen and the University of Adelaide in Australia and as Board member of Isogenica Ltd.

Other assignments: Göran Forsberg is CEO of Cantargia AB since 2014.

Shareholding: 1,369 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Hege Hellström

Non-Executive Member of the Board

Board member since May 2024. Hege Hellström has a bachelor's degree in medical laboratory science from Oslo Metropolitan University in Norway.

Previous experience: Hege Hellström has over 30 years of experience in sales, marketing, strategic development and business management within the pharmaceutical industry, with particular experience in kidney medicine. She is currently Chief Commercial Officer at Advicenne, a French pharmaceutical company, as well as Partner at Belnor BVBA, a consulting and investment company.

Previously, Hege Hellström held senior positions within several pharmaceutical companies, including the role of head of EMENAR (Europe, the Middle East, North Africa and Russia) at SOBI. She has also been global business area manager for Cardiovascular, Vice President Renal Europe and Head of Regional Liaisons at Sanofi, as well as Vice President Renal & Endocrine Europe and General Manager Benelux at Genzyme. Before that, she worked in various positions at Baxter for 13 years.

Other assignments: Chief Commercial Officer at Advicenne and Partner at Belnor BVBA. Board member of Camurus AB since 2020, Vivesto AB since 2019 and InflaRx GmbH since 2023.

Shareholding: 3,000 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Johannes Hulthe

Non-Executive Member of the board

Board member since May 2019. Born 1970. Johannes Hulthe is a PhD and MSc in Economics.

Previous experience: Johannes Hulthe has more than 17 years of experience from the pharmaceutical industry. Lecturer in cardiovascular prevention at Sahlgrenska University Hospital, Gothenburg. Johannes Hulthe was under 13 years employed at AstraZeneca and, when he finished in 2014, held the role of chief (vice president) in clinical drug development for heart vessels, metabolism and kidney disease.

Other assignments: Co-founder, CEO and board member of Antaros Medical AB, board member of Antaros Holding AB, chairman of Antaros Renostic AB.

Shareholding: 6,000 shares

Independent in relation to the company and its senior management as well as to its major shareholders.